Artery-Directed chemo plus immunotherapy shows promise in stomach cancer trial
NCT ID NCT05593458
First seen Jun 13, 2026 · Last updated Jun 15, 2026 · Updated 1 time
Summary
This study tests if giving chemotherapy directly into the artery that feeds the stomach tumor, along with an immunotherapy drug, works better than standard IV chemo plus immunotherapy for locally advanced stomach cancer. About 190 adults with stage 3 stomach cancer will be randomly assigned to one of the two treatment groups. The goal is to see if the artery-directed approach leads to more tumor shrinkage before surgery and better long-term survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED GASTRIC CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Gastrointestinal Department of Second Affiliated Hospital of Zhejiang University
RECRUITINGHangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.